Vol 66, No 3 (2015)
Original paper
Published online: 2015-07-01

open access

Page views 1858
Article views/downloads 1991
Get Citation

Connect on Social Media

Connect on Social Media

Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.

Robert Krysiak, Anna Gdula-Dymek, Bogdan Marek, Bogusław Okopień
DOI: 10.5603/EP.2015.0029
Pubmed: 26136131
Endokrynol Pol 2015;66(3):224-230.


Introduction: Statins and fibrates reduce monocyte release of proinflammatory cytokines, but it remains unknown whether this effect is sex dependent.

Material and methods: We retrospectively analysed age-, weight-, and lipid-matched populations of type 2 diabetic patients of both sexes, who, because of atherogenic dyslipidaemia, were treated with simvastatin (40 mg daily), fenofibrate (200 mg daily), or simvastatin plus fenofibrate. Monocyte release of tumour necrosis factor alpha (TNF-alpha), inteleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 (MCP-1), as well as circulating levels of high-sensitivity C-reactive protein (hsCRP) and free fatty acids (FFA) were assessed separately for men and women before and after 12 weeks of treatment.

Results: Baseline monocyte release of TNF-alpha, interleukin-1beta, interleukin-6, and MCP-1, as well as plasma hsCRP and FFA levels were comparable in both sexes. Simvastatin, fenofibrate, and simvastatin/fenofibrate combination therapy reduced monocyte release of TNF-alpha, inteleukin-1beta, interleukin-6, and MCP-1, with no difference between the treatment groups. The impact of simvastatin and fenofibrate administered alone on monocyte cytokine release and systemic inflammation did not differ between the men and women. The effect of simvastatin/fenofibrate combination therapy on monocyte release of interleukin-6 and MCP-1 was more pronounced in the male population. The impact of simvastatin administered together with fenofibrate on TNF-alpha, interleukin-1beta, and hsCRP was also stronger in the men than in the women, but the difference did not reach the level of significance.

Conclusions: The obtained results suggest that sex differences determine the strength of the monocyte-suppressing effect of simvastatin/ /fenofibrate combination therapy in type 2 diabetic patients with atherogenic dyslipidaemia. (Endokrynol Pol 2015; 66 (3): 224–230)